Redeye provides an update following Iconovo’s Q1 report. We are positive about the report as the results came in better than anticipated; however, we argue the report did not include any major surprises. Furthermore, we look forward to an upcoming outlicensing deal for ICOpre, which we argue could act as a solid near-term trigger for the share and decrease the valuation gap to our base case.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Iconovo Q1 - Solid quarter with a near-term catalyst on the horizon

© Modular Finance, source Nordic Press Releases